Forskning ved Københavns Universitet - Københavns Universitet

Forside

The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab - validation against two external data sources

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The Danish National Prescription Registry in studies of a biological pharmaceutical : palivizumab - validation against two external data sources. / Haerskjold, Ann; Stokholm, Lonny Merete; Way, Susanne; Malham, Mikkel; Hallas, Jesper; Pedersen, Lars; Stensballe, Lone Graff.

I: Clinical Epidemiology, Bind 7, 2015, s. 305-312.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Haerskjold, A, Stokholm, LM, Way, S, Malham, M, Hallas, J, Pedersen, L & Stensballe, LG 2015, 'The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab - validation against two external data sources', Clinical Epidemiology, bind 7, s. 305-312. https://doi.org/10.2147/CLEP.S73355

APA

Haerskjold, A., Stokholm, L. M., Way, S., Malham, M., Hallas, J., Pedersen, L., & Stensballe, L. G. (2015). The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab - validation against two external data sources. Clinical Epidemiology, 7, 305-312. https://doi.org/10.2147/CLEP.S73355

Vancouver

Haerskjold A, Stokholm LM, Way S, Malham M, Hallas J, Pedersen L o.a. The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab - validation against two external data sources. Clinical Epidemiology. 2015;7:305-312. https://doi.org/10.2147/CLEP.S73355

Author

Haerskjold, Ann ; Stokholm, Lonny Merete ; Way, Susanne ; Malham, Mikkel ; Hallas, Jesper ; Pedersen, Lars ; Stensballe, Lone Graff. / The Danish National Prescription Registry in studies of a biological pharmaceutical : palivizumab - validation against two external data sources. I: Clinical Epidemiology. 2015 ; Bind 7. s. 305-312.

Bibtex

@article{98921711eb7c49d587bb1882b65a7959,
title = "The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab - validation against two external data sources",
abstract = "BACKGROUND: National prescription databases are important tools in pharmacoepidemiological studies investigating potential long-term adverse events after drug use. Palivizumab is a biological pharmaceutical used as passive prophylaxis against severe infection with respiratory syncytial virus in high-risk children.OBJECTIVE: To assess the registration of palivizumab in the Danish National Prescription Registry (DNPR) and to examine if palivizumab reimbursement data obtained from the Danish Health and Medicines Authority could serve as a supplement to data from the DNPR.METHODS: Registration of palivizumab exposure in the DNPR between 1999 and 2010 was compared to two external data sources: registration of palivizumab exposure in medical records, and palivizumab reimbursement data.RESULTS: During the study period, 182 children with palivizumab exposure were registered in the DNPR. A total of 207 children were registered for palivizumab reimbursement. The sensitivity of palivizumab registration in the DNPR was 26{\%} (20{\%}-34{\%}), and the specificity of no palivizumab registration in the DNPR was 97{\%} (94{\%}-99{\%}), with data from the medical record as the reference. Palivizumab registration sensitivity in reimbursement data was 29{\%} (22{\%}-36{\%}), and the specificity of no palivizumab registration in the DNPR was 97{\%} (94{\%}-99{\%}), with data from the medical record as the reference.CONCLUSION: Exposure to palivizumab was underestimated in the DNPR. Reimbursement data are a readily accessible data supplement, which only slightly increased the sensitivity of palivizumab registration in the DNPR. Our findings underline the need to improve DNPR information concerning drugs administered in hospitals.",
keywords = "Journal Article",
author = "Ann Haerskjold and Stokholm, {Lonny Merete} and Susanne Way and Mikkel Malham and Jesper Hallas and Lars Pedersen and Stensballe, {Lone Graff}",
year = "2015",
doi = "10.2147/CLEP.S73355",
language = "English",
volume = "7",
pages = "305--312",
journal = "Clinical Epidemiology",
issn = "1179-1349",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - The Danish National Prescription Registry in studies of a biological pharmaceutical

T2 - palivizumab - validation against two external data sources

AU - Haerskjold, Ann

AU - Stokholm, Lonny Merete

AU - Way, Susanne

AU - Malham, Mikkel

AU - Hallas, Jesper

AU - Pedersen, Lars

AU - Stensballe, Lone Graff

PY - 2015

Y1 - 2015

N2 - BACKGROUND: National prescription databases are important tools in pharmacoepidemiological studies investigating potential long-term adverse events after drug use. Palivizumab is a biological pharmaceutical used as passive prophylaxis against severe infection with respiratory syncytial virus in high-risk children.OBJECTIVE: To assess the registration of palivizumab in the Danish National Prescription Registry (DNPR) and to examine if palivizumab reimbursement data obtained from the Danish Health and Medicines Authority could serve as a supplement to data from the DNPR.METHODS: Registration of palivizumab exposure in the DNPR between 1999 and 2010 was compared to two external data sources: registration of palivizumab exposure in medical records, and palivizumab reimbursement data.RESULTS: During the study period, 182 children with palivizumab exposure were registered in the DNPR. A total of 207 children were registered for palivizumab reimbursement. The sensitivity of palivizumab registration in the DNPR was 26% (20%-34%), and the specificity of no palivizumab registration in the DNPR was 97% (94%-99%), with data from the medical record as the reference. Palivizumab registration sensitivity in reimbursement data was 29% (22%-36%), and the specificity of no palivizumab registration in the DNPR was 97% (94%-99%), with data from the medical record as the reference.CONCLUSION: Exposure to palivizumab was underestimated in the DNPR. Reimbursement data are a readily accessible data supplement, which only slightly increased the sensitivity of palivizumab registration in the DNPR. Our findings underline the need to improve DNPR information concerning drugs administered in hospitals.

AB - BACKGROUND: National prescription databases are important tools in pharmacoepidemiological studies investigating potential long-term adverse events after drug use. Palivizumab is a biological pharmaceutical used as passive prophylaxis against severe infection with respiratory syncytial virus in high-risk children.OBJECTIVE: To assess the registration of palivizumab in the Danish National Prescription Registry (DNPR) and to examine if palivizumab reimbursement data obtained from the Danish Health and Medicines Authority could serve as a supplement to data from the DNPR.METHODS: Registration of palivizumab exposure in the DNPR between 1999 and 2010 was compared to two external data sources: registration of palivizumab exposure in medical records, and palivizumab reimbursement data.RESULTS: During the study period, 182 children with palivizumab exposure were registered in the DNPR. A total of 207 children were registered for palivizumab reimbursement. The sensitivity of palivizumab registration in the DNPR was 26% (20%-34%), and the specificity of no palivizumab registration in the DNPR was 97% (94%-99%), with data from the medical record as the reference. Palivizumab registration sensitivity in reimbursement data was 29% (22%-36%), and the specificity of no palivizumab registration in the DNPR was 97% (94%-99%), with data from the medical record as the reference.CONCLUSION: Exposure to palivizumab was underestimated in the DNPR. Reimbursement data are a readily accessible data supplement, which only slightly increased the sensitivity of palivizumab registration in the DNPR. Our findings underline the need to improve DNPR information concerning drugs administered in hospitals.

KW - Journal Article

U2 - 10.2147/CLEP.S73355

DO - 10.2147/CLEP.S73355

M3 - Journal article

C2 - 26056490

VL - 7

SP - 305

EP - 312

JO - Clinical Epidemiology

JF - Clinical Epidemiology

SN - 1179-1349

ER -

ID: 172265755